Details der Publikation - PROTECT: studio randomizzato con idrossiclorochina vs osservazione per la prevenzione e il trattamento precoce della malattia da coronavirus (COVID-19)

PROTECT: studio randomizzato con idrossiclorochina vs osservazione per la prevenzione e il trattamento precoce della malattia da coronavirus (COVID-19) : PROTECT: A randomized study with Hydroxychloroquine versus observational support for prevention or early phase treatment of Coronavirus disease (COVID-19). - PROTECT

Medienart:	Klinische Studie

Erscheinungsjahr:	2022
Erschienen:	2022

Enthalten in:	WHO International Clinical Trials Registry Platform - (2022) vom: 14. März Zur Gesamtaufnahme - year:2022

Sprache:	Italienisch

Links:	Volltext [kostenfrei]

Themen:	610 Medical Condition: Group 1: SARS-CoV-2-exposed subjects, as household members/contacts of COVID-19 patientsGroup 2: Patients with COVID-19 asymptomatic or paucisymptomatic in home situation MedDRA version: 23.0Level: LLTClassification code 10053983Term: Corona virus infectionSystem Organ Class: 100000004862;Therapeutic area: Diseases [C] - Virus Diseases [C02] Phase: Phase 2 Recruitment Status: Not yet recruiting Study Type: Interventional

Anmerkungen:	WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 24-06-2020, Last updated: 2022-11-24

ICTRP ID:	EUCTR2020-001501-24-IT IRST100.47

Förderinstitution / Projekttitel:

PPN (Katalog-ID):	CTG004712161

Internformat


LEADER	01000caa a22002652 4500
001	CTG004712161
003	DE-627
005	20230425175153.0
007	cr uuu---uuuuu
008	210507s2022 xx \|\|\|\|\|o 00\| \|\|ita c
035			\|a (DE-627)CTG004712161
035			\|a (UBBS_Klinische_Studien_WHO)EUCTR2020-001501-24-IT
035			\|a (UBBS_Klinische_Studien_WHO)IRST100.47
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a ita
245	1	0	\|a PROTECT: studio randomizzato con idrossiclorochina vs osservazione per la prevenzione e il trattamento precoce della malattia da coronavirus (COVID-19) \|b PROTECT: A randomized study with Hydroxychloroquine versus observational support for prevention or early phase treatment of Coronavirus disease (COVID-19). - PROTECT
264		1	\|c 2022
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 24-06-2020, Last updated: 2022-11-24
650		4	\|a Medical Condition: Group 1: SARS-CoV-2-exposed subjects, as household members/contacts of COVID-19 patientsGroup 2: Patients with COVID-19 asymptomatic or paucisymptomatic in home situation MedDRA version: 23.0Level: LLTClassification code 10053983Term: Corona virus infectionSystem Organ Class: 100000004862;Therapeutic area: Diseases [C] - Virus Diseases [C02]
650		4	\|a Study Type: Interventional
650		4	\|a Phase: Phase 2
650		4	\|a Recruitment Status: Not yet recruiting
650		4	\|a 610
773	0	8	\|i Enthalten in \|t WHO International Clinical Trials Registry Platform \|g (2022) vom: 14. März
773	1	8	\|g year:2022 \|g day:14 \|g month:03
856	4	0	\|u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001501-24 \|z kostenfrei \|3 Volltext
912			\|a GBV_CTG
912			\|a SSG-OLC-PHA
951			\|a AR
952			\|j 2022 \|b 14 \|c 03

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände